GlaxoSmithKline Plc’s widely prescribed drug Advair is safe enough for treating asthma but two lesser-used medicines are too risky, a U.S. advisory panel ruled on Thursday. Evidence of asthma-related deaths and serious complications led the panel of experts to warn against continued use of Glaxo’s Serevent and Novartis AG’s Foradil for adults, adolescents and children with asthma.
Archive for December 15th, 2008
UPDATE 3-US FDA panel: Two asthma drugs risky but Advair OK
Author: adminDec 15
